Last Saturday (23), the founder of The Medulloblastoma Initiative (MBI), Fernando Goldsztein, participated in the Present-Future session of Snola 2024, the largest scientific event on neuro-oncology in Latin America. The session addressed brain cancer in pediatric oncology and was attended by doctors and researchers from Brazil, the USA and Canada. MBI’s participation in this important event is a recognition of the innovative model of research support that the initiative has been developing.
During the session, Goldsztein presented the MBI and the advances made by the research consortium that the initiative supports — the Cure Group 4 Consortium, which brings together renowned experts and laboratories from the US, Canada and Germany. Among the main achievements discussed were the submission of two protocols for clinical trials of innovative treatments to the Food and Drug Administration (FDA) in less than three years. The urgent need for research resources in this area and the limitations of current treatments were also discussed.
